Lisa Anne Carey, MD, talks with Otto Metzger, MD, about the results of the phase 3 PATINA trial, which evaluated the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy vs. anti-HER2 therapy after induction treatment for hormone receptor-positive (HR+)/HER-positive metastatic breast cancer.
▷ Estimated Read Time:
1–2 minutes
SABCS Snippets: Results from the AFT-38 PATINA trial
Connect with thousands of basic and translational scientists, multidisciplinary clinicians, regulatory and pharmaceutical partners, survivors, and patient advocates at the 49th annual San Antonio Breast Cancer Symposium. Complete your registration by Friday, September 25, to take advantage of discounted early registration rates.
Share: